ArticleOncoimmunology2015
Trial watch: Naked and vectored DNA-based anticancer vaccines.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Digital Pathology for Better Clinical Practice.Cancers · 2024Review
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Cancer immunotherapy of Wilms tumor: a narrative review.Future oncology (London, England) · 2024Review
- Global research trends in immunotherapy for head and neck neoplasms: A scientometric study.Heliyon · 2023Article
- Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.Oncoimmunology · 2023Review
- Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines.NPJ vaccines · 2021Review
- Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy.Drug delivery and translational research · 2021Review
- Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy.Oncotarget · 2020Article
- Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.Frontiers in immunology · 2018Review
- Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.Oncotarget · 2017Article
- Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.Journal of virology · 2017Article
- Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.Cancer immunology, immunotherapy : CII · 2017Article
- Immunotherapy for Head and Neck Squamous Cell Carcinoma.Current oral health reports · 2016Article
- Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.Gynecologic oncology · 2016Review
- P62: An emerging oncotarget for osteolytic metastasis.Journal of bone oncology · 2016Review
- MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.PloS one · 2016Article
- DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.Oncotarget · 2015Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is to drive the synthesis of TAAs in the context of an immunostimulatory milieu, resulting in the (re-)elicitation of a tumor-targeting immune response. In spite of encouraging preclinical results, the clinical efficacy of DNA-based vaccines employed as standalone immunotherapeutic interventions in cancer patients appears to be limited. Thus, efforts are currently being devoted to the development of combinatorial regimens that allow DNA-based anticancer vaccines to elicit clinically relevant immune responses. Here, we discuss recent advances in the preclinical and clinical development of this therapeutic paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.